Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037692 | 0.85 | ALDH1A1 (0.52) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL28500432 | 0.85 | ALDH1A1 (0.52) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL11211091 | 0.84 | THRB (0.45) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL28957144 | 0.82 | CYP1A2 (0.44) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL8232146 | 0.80 | TSHR (0.55) | THRBKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL31282824 | 0.80 | ALDH1A1 (0.52) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL9586044 | 0.78 | CYP1A2 (0.74) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL497168 | 0.78 | THRB (0.54) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL3185113 | 0.77 | THRB (0.43) | THRBKMT2AALDH1A1CYP1A2MEN1 | |
| SCHEMBL8751907 | 0.77 | ALDH1A1 (0.44) | THRBKMT2AALDH1A1CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4853220-A | Protein isolated from blood, process for preparing said protein, aantibodies against said new protein, and pharmaceutical compositions containing said protein or said antibodies | NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGERASTNATUURWETE NSCHAPPELIJK ONDERZOEK (NL) | 1989-08-01 | — | — | US | claimed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-12540946-B2 | Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample | COMPLETE OMICS INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4634392-A1 | MODIFIED HERPES SIMPLEX VIRUS TYPE 1 | EG 427 (FR) | 2025-10-22 | — | — | EP | disclosed |
| EP-4630547-A1 | VIRAL VECTOR ENCODING GAD FOR TREATING SPASTICITY | EG 427 (FR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626489-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-0625988-A4 | ALLOSTERIC MODULATORS OF THE NMDA RECEPTOR. | MACCECCHINI MARIA LUISA (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1998000443-A1 | THROMBIN INHIBITORS | TRIGEN LIMITED (GB) | 1998-01-08 | — | — | WO | disclosed |
| EP-0809650-A1 | SERINE PROTEASE INHIBITORS | ELLERMAN PHARMACEUTICALS LIMITED (GB) | 1997-12-03 | — | — | EP | disclosed |
| US-5610278-A | Process for producing a coagulation active complex of factor VIII fragments | NOVO NORDISK A/S (DK) | 1997-03-11 | — | — | US | disclosed |
| WO-1996025427-A1 | SERINE PROTEASE INHIBITORS | ELLERMAN PHARMACEUTICALS LIMITED (GB) | 1996-08-22 | — | — | WO | disclosed |
| US-5460835-A | Aluminum salts in the treatment of bone disease | DUKE UNIVERSITY (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0625988-A1 | ALLOSTERIC MODULATORS OF THE NMDA RECEPTOR | MACCECCHINI, Maria-Luisa (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994007914-A1 | ALLOSTERIC MODULATORS OF THE NMDA RECEPTOR | MACCECCHINI MARIA LUISA (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5019401-A | Aluminum salts in the treatment of bone disease | DUKE UNIVERSITY (US) | 1991-05-28 | — | — | US | disclosed |
| US-4149936-A | IMMOBILIZED CELLS | CORNING GLASS WORKS (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540946-B2 | Methods and systems for detecting and quantifying large number of molecule biomarkers from a body fluid sample | MYADM, EPCAM, CD14 | THRB 568/4885KMT2A 3845/4885ALDH1A1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.